Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia
- PMID: 15976757
- DOI: 10.1016/j.lab.2005.03.005
Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia
Abstract
Among activating class III receptor tyrosine kinase (Flt3) mutations, internal tandem duplications of Flt3 (Flt3-ITD) are detected in about 25% of patients with acute myeloid leukemia (AML). In contrast, mutations within the tyrosine kinase domain of Flt3 (Flt3-TKD mutations) are less frequent (approximately 7%), and there are only limited data on the frequency of recently demonstrated activating Flt3 point mutation at codon 592 (Flt3-V592A mutation). We evaluated a new approach for rapid screening of Flt3-TKD and Flt3-V592A mutations using the fluorescence resonance energy transfer (FRET) principle in a group of 122 patients. Based on individual Flt3-TKD mutations, we designed patient-specific primers to perform a highly sensitive polymerase chain reaction (PCR) assay for rapid detection of minimal residual disease (MRD). We also used a model system with MonoMac-6 cells carrying the Flt3-V592A mutation to establish a mutation-specific real-time PCR approach also for this molecular aberration. We identified 9 cases (8%) of Flt3-TKD mutations (5 cases of mutation D835Y, 3 cases of mutation D835H, and 1 case of mutation Del836), and no cases of Flt3-V592A mutation. Screening for Flt3-TKD mutations with fluorescent probes is equivalent to conventional screening using standard PCR followed by EcoRV restriction. We present a real-time PCR protocol that can be used for MRD analyses based on individual Flt3-TKD mutations. Examples of MRD analyses are presented for all 3 subtypes of Flt3-TKD mutation identified in this study. In summary, we demonstrate new methodological approaches for rapid screening of Flt3 point mutations and for detection of MRD based on patient-specific Flt3-TKD mutations.
Similar articles
-
[Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia].Zhonghua Xue Ye Xue Za Zhi. 2005 Jun;26(6):335-8. Zhonghua Xue Ye Xue Za Zhi. 2005. PMID: 16185475 Chinese.
-
Rapid and sensitive detection of internal tandem duplication and activating loop mutations of FLT3.Br J Haematol. 2005 Jul;130(2):203-8. doi: 10.1111/j.1365-2141.2005.05589.x. Br J Haematol. 2005. PMID: 16029448
-
Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype.Oncogene. 2005 Feb 24;24(9):1580-8. doi: 10.1038/sj.onc.1208344. Oncogene. 2005. PMID: 15674343
-
FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia.Acta Haematol. 2004;112(1-2):68-78. doi: 10.1159/000077561. Acta Haematol. 2004. PMID: 15179006 Review.
-
The role of FLT3 in haematopoietic malignancies.Nat Rev Cancer. 2003 Sep;3(9):650-65. doi: 10.1038/nrc1169. Nat Rev Cancer. 2003. PMID: 12951584 Review.
Cited by
-
An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment.Oncol Rev. 2012 Apr 17;6(1):e8. doi: 10.4081/oncol.2012.e8. eCollection 2012 Mar 5. Oncol Rev. 2012. PMID: 25992210 Free PMC article. Review.
-
"FLipping" the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors.Cancers (Basel). 2022 Jul 13;14(14):3398. doi: 10.3390/cancers14143398. Cancers (Basel). 2022. PMID: 35884458 Free PMC article. Review.
-
Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML).J Cancer Res Clin Oncol. 2014 Aug;140(8):1391-7. doi: 10.1007/s00432-014-1666-7. Epub 2014 Apr 12. J Cancer Res Clin Oncol. 2014. PMID: 24728467 Free PMC article.
-
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.Blood. 2008 Feb 1;111(3):1552-9. doi: 10.1182/blood-2007-08-107946. Epub 2007 Oct 16. Blood. 2008. PMID: 17940205 Free PMC article.
-
Clinical Implications of the FLT3-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell Transplantation.Cancers (Basel). 2023 Feb 18;15(4):1312. doi: 10.3390/cancers15041312. Cancers (Basel). 2023. PMID: 36831653 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous